nach oben

Tumor Biology

Erschienen in:

04.10.2016 | Original Article

A humanized chimeric antibody Hai178 targeted to the β subunit of F1F0 ATP synthase

verfasst von: Chen Chen, Hui Liang, Xinmei Liao, Jian Pan, Jianhe Chen, Shibi Zhao, Yan Xu, Yun Wu, Jian Ni

Erschienen in: Tumor Biology | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Inhibition of tumor vasculature is an effective strategy for cancer therapy. Angiostatin could suppress tumor growth and metastasis by binding and inhibiting F1F0 ATP synthase on the endothelial cell surface. We previously screened a monoclonal antibody (McAb, McAb178-5G10), which specifically bound to ATPase on the surface of cells and showed an angiostatin-like activity. Here, we further generated a panel of CHO-mAb subclone stable expressing a humanized chimeric antibody from hybridoma cell McAb178-5G10 by gene engineer. And then, we successfully expressed the humanized antibody Hai178 at high level in a 5-L wave bioreactor. The vitro results showed that Hai178 retained the specific binding and antitumor activity of murine antibody. Furthermore, Hai178 also had a tumor therapeutic effect in tumor xenografts. These results paved the way for Hai178 as a therapeutic antibody in clinic.

Burwick NR. An inhibitor of the F1 subunit of ATP synthase (IF1) modulates the activity of angiostatin on the endothelial cell surface. J Biol Chem. 2004;280:1740–5.CrossRefPubMedPubMedCentral

Ma Z, Cao M, Liu Y, He Y, Wang Y, Yang C, et al. Mitochondrial F1Fo-ATP synthase translocates to cell surface in hepatocytes and has high activity in tumor-like acidic and hypoxic environment. Acta. Biochim Biophys. 2010;42:530–7.

Champagne E, Martinez LO, Collet X, Barbaras R. Ecto-F1Fo ATP synthase/F1 ATPase: metabolic and immunological functions. Curr Opin Lipidol. 2006;17:279–84.CrossRefPubMed

Moser L, Kenan DJ, Ashley TA, Roy JA, Goodman MD, Misra UK, et al. Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci U S A. 2001;98:6656–61.CrossRefPubMedPubMedCentral

Yuan J, Zhang C, Fang S, Zhuang Z, Ling S, Wang SA. Monoclonal antibody against F1-F0 atp synthase beta subunit. Hybridoma. 2012;31:352–7.CrossRefPubMed

Fliedner SM, Yang C, Thompson E, Abu-Asab M, Hsu CM, Lampert G, et al. Potential therapeutic target for malignant paragangliomas: ATP synthase on the surface of paraganglioma cells. Am J Cancer Res. 2015;5:1558–70.PubMedPubMedCentral

Zhang X, Gao F, LL Y, Peng Y, Liu HH, Liu JY, et al. Dual functions of a monoclonal antibody against cell surface F1F0 ATP synthase on both HUVEC and tumor cells. Acta Pharmacol Sin. 2008;29:942–50.CrossRefPubMed

Scotet E, Martinez LO, Grant E, Barbaras R, Jeno P, Guiraud M, et al. Tumor recognition following vgamma 9vdelta2 t cell receptor interactions with a surface F1-atpase-related structure and apolipoprotein a-i. Immunity. 2005;22:71–80.CrossRefPubMed

Deshpande M, Notari L, Subramanian P, Notario V, Becerra SP. Inhibition of tumor cell surface atp synthesis by pigment epithelium-derived factor: implications for antitumor activity. Int J Oncol. 2012;41:219–27.PubMedPubMedCentral

10.

Chi SL, Pizzo SV. Angiostatin is directly cytotoxic to tumor cells at low extracellular ph: a mechanism dependent on cell surface-associated atp synthase. Cancer Res. 2006;66:875–82.CrossRefPubMed

11.

Chi SL, Wahl ML, Mowery YM, Shan S, Mukhopadhyay S, Hilderbrand SC, et al. Angiostatin-like activity of a monoclonal antibody to the catalytic subunit of F1F0 ATP synthase. Cancer Res. 2007;67:4716–24.CrossRefPubMed

12.

Moser TL, Stack SM, Asplin I, Enghild JJ, Højrup P, Everitt L, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A. 1999;96:2811–6.CrossRefPubMedPubMedCentral

13.

Mowery YM, Pizzo SV. Targeting cell surface F1F0 ATP synthase in cancer therapy. Cancer Biol Ther. 2008;7:1836–8.CrossRefPubMed

14.

Barbato S, Sgarbi G, Gorini G, Baracca A, Solaini G. The inhibitor protein (IF1) of the F1F0-ATPase modulates human osteosarcoma cell bioenergetics. J Biol Chem. 2015;290:6338–43.CrossRefPubMedPubMedCentral

15.

Pan J, Sun LC, Tao YF, Zhou Z, Du XL, Peng L, et al. ATP synthase ecto-α-subunit: a novel therapeutic target for breast cancer. J Transl Med. 2011;(9):211.

16.

Wang J, Han Y, Liang J, Cheng X, Yan L, Wang Y, et al. Effect of a novel inhibitory mAb against β-subunit of F1F0 ATPase on HCC. Cancer Biol Ther. 2008;7:1829–35.CrossRefPubMed

17.

Wang WJ, Ma Z, Liu YW, He YQ, Wang YZ, Yang CX, et al. A monoclonal antibody (Mc178-ab) targeted to the ecto-ATP synthase beta-subunit-induced cell apoptosis via a mechanism involving the MAPKase and Akt pathways. Clin Exp Med. 2012;12:3–12.CrossRefPubMed

18.

Wang WJ, Shi XX, Liu YW, He YQ, Wang YZ, Yang CX, et al. The mechanism underlying the effects of the cell surface ATP synthase on the regulation of intracellular acidification during acidosis. J Cell Biochem. 2013;114:1695–703.CrossRefPubMed

19.

Zhao WL, Wang J, Tao YF, Feng X, Li YH, Zhu XM, et al. Inhibition of the ecto-beta subunit of F1F0-ATPase inhibits proliferation and induces apoptosis in acute myeloid leukemia cell lines. J Exp Clin Cancer Res. 2012;31:31–92.CrossRefPubMedPubMedCentral

20.

Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, et al. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res. 2009;15:1585–92.CrossRefPubMedPubMedCentral

21.

Chusainow J, Yang YS, Yeo JH, Toh PC, Asvadi P, Wong NCA. Study of monoclonal antibody-producing cho cell lines: what makes a stable high producer? Biotechnol Bioeng. 2009;102:1182–96.CrossRefPubMed

22.

Sleiman RJ, Gray PP, McCall MN, Codamo J, Sunstrom NA. Accelerated cell line development using two-color fluorescence activated cell sorting to select highly expressing antibody-producing clones. Biotechnol Bioeng. 2008;99:578–87.CrossRefPubMed

23.

Tabuchi H, Sugiyama T, Tanaka S, Tainaka S. Overexpression of taurine transporter in chinese hamster ovary cells can enhance cell viability and product yield, while promoting glutamine consumption. Biotechnol Bioeng. 2010;107:998–1003.CrossRefPubMed

24.

Liang H, Li X, Chen B, Wang B, Zhao Y, Zhuang Y, et al. A collagen-binding egfr single-chain fv antibody fragment for the targeted cancer therapy. J Control Release. 2015;209:101–9.CrossRefPubMed

25.

Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1:2315–9.CrossRefPubMed

26.

Balin-Gauthier D, Delord JP, Rochaix P, Mallard V, Thomas F, Hennebelle I, et al. Vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of egfr. Cancer Chemother Pharmacol. 2006;57:709–18.CrossRefPubMed

27.

De Boeck A, Pauwels P, Hensen K, Rummens JL, Westbroek W, Hendrix A, et al. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/her3 signalling. Gut. 2013;62:550–60.CrossRefPubMed

28.

Ohsakaya S, Fujikawa M, Hisabori T, Yoshida M. Knockdown of dapit (diabetes-associated protein in insulin-sensitive tissue) results in loss of atp synthase in mitochondria. J Biol Chem. 2011;286:20292–6.CrossRefPubMedPubMedCentral

29.

Ortega AD, Willers IM, Sala S, Cuezva JM. Human G3BP1 interacts with beta-F1-ATPase mRNA and inhibits its translation. J. Cell Sci. J Cell Sci. 2010;123:2685–96.CrossRefPubMed

30.

Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol. 2009;27:331–7.CrossRefPubMed

31.

Calvo B, Zuñiga L. Therapeutic monoclonal antibodies: strategies and challenges for biosimilarsdevelopment. Curr Med Chem. 2012;2012:4445–50.CrossRef

32.

Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer. 2007;109:170–9.CrossRefPubMed

33.

Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278–7.CrossRefPubMed

Titel: A humanized chimeric antibody Hai178 targeted to the β subunit of F1F0 ATP synthase
verfasst von: Chen Chen
Hui Liang
Xinmei Liao
Jian Pan
Jianhe Chen
Shibi Zhao
Yan Xu
Yun Wu
Jian Ni
Publikationsdatum: 04.10.2016
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 12/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-5423-1

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

A humanized chimeric antibody Hai178 targeted to the β subunit of F1F0 ATP synthase

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2016

MiR-200 suppresses metastases of colorectal cancer through ZEB1

MiR-153 regulates metastases of gastric cancer through Snail

MicroRNA-92 promotes invasion and chemoresistance by targeting GSK3β and activating Wnt signaling in bladder cancer cells

Identification of microRNAs (miR-203/miR-7) as potential markers for the early detection of lymph node metastases in patients with cervical cancer

Downregulation of miR-133b/miR-503 acts as efficient prognostic and diagnostic factors in patients with osteosarcoma and these predictor biomarkers are correlated with overall survival

Fluorouracil induces autophagy-related gastric carcinoma cell death through Beclin-1 upregulation by miR-30 suppression

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie